Product Development
First biomarker data from pioneering tau program in Alzheimer’s cloud use of antibodies for the target
Genentech, AC Immune look ahead to data in moderate Alzheimer’s for semorinemab
Nov 10, 2020 | 2:54 AM GMT
Data presented at the annual CTAD meeting hint that anti-tau therapy semorinemab from Genentech and AC Immune may have engaged